CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches.
Agonist
Antagonist
Antibody
CD40
Crystal structure
Journal
BMC molecular and cell biology
ISSN: 2661-8850
Titre abrégé: BMC Mol Cell Biol
Pays: England
ID NLM: 101741148
Informations de publication
Date de publication:
05 08 2019
05 08 2019
Historique:
received:
17
04
2019
accepted:
17
07
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
18
1
2020
Statut:
epublish
Résumé
CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. CD40 antagonists are currently being explored for the treatment of autoimmune diseases and several anti-CD40 agonist mAbs have entered clinical development for oncological indications. To better understand the mode of action of anti-CD40 mAbs, we have determined the x-ray crystal structures of the ABBV-323 (anti-CD40 antagonist, ravagalimab) Fab alone, ABBV-323 Fab complexed to human CD40 and FAB516 (anti-CD40 agonist) complexed to human CD40. These three crystals structures 1) identify the conformational CD40 epitope for ABBV-323 recognition 2) illustrate conformational changes which occur in the CDRs of ABBV-323 Fab upon CD40 binding and 3) develop a structural hypothesis for an agonist/antagonist switch in the LCDR1 of this proprietary class of CD40 antibodies. The structure of ABBV-323 Fab demonstrates a unique method for antagonism by stabilizing the proposed functional antiparallel dimer for CD40 receptor via novel contacts to LCDR1, namely residue position R32 which is further supported by a closely related agonist antibody FAB516 which shows only monomeric recognition and no contacts with LCDR1 due to a mutation to L32 on LCDR1. These data provide a structural basis for the full antagonist activity of ABBV-323.
Sections du résumé
BACKGROUND
CD40 is a 48 kDa type I transmembrane protein that is constitutively expressed on hematopoietic cells such as dendritic cells, macrophages, and B cells. Engagement of CD40 by CD40L expressed on T cells results in the production of proinflammatory cytokines, induces T helper cell function, and promotes macrophage activation. The involvement of CD40 in chronic immune activation has resulted in CD40 being proposed as a therapeutic target for a range of chronic inflammatory diseases. CD40 antagonists are currently being explored for the treatment of autoimmune diseases and several anti-CD40 agonist mAbs have entered clinical development for oncological indications.
RESULTS
To better understand the mode of action of anti-CD40 mAbs, we have determined the x-ray crystal structures of the ABBV-323 (anti-CD40 antagonist, ravagalimab) Fab alone, ABBV-323 Fab complexed to human CD40 and FAB516 (anti-CD40 agonist) complexed to human CD40. These three crystals structures 1) identify the conformational CD40 epitope for ABBV-323 recognition 2) illustrate conformational changes which occur in the CDRs of ABBV-323 Fab upon CD40 binding and 3) develop a structural hypothesis for an agonist/antagonist switch in the LCDR1 of this proprietary class of CD40 antibodies.
CONCLUSIONS
The structure of ABBV-323 Fab demonstrates a unique method for antagonism by stabilizing the proposed functional antiparallel dimer for CD40 receptor via novel contacts to LCDR1, namely residue position R32 which is further supported by a closely related agonist antibody FAB516 which shows only monomeric recognition and no contacts with LCDR1 due to a mutation to L32 on LCDR1. These data provide a structural basis for the full antagonist activity of ABBV-323.
Identifiants
pubmed: 31382872
doi: 10.1186/s12860-019-0213-4
pii: 10.1186/s12860-019-0213-4
pmc: PMC6683420
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antigen-Antibody Complex
0
CD40 Antigens
0
Immunoglobulin Fab Fragments
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Références
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):235-42
pubmed: 21460441
Transplantation. 2004 Feb 15;77(3):460-2
pubmed: 14966427
J Biol Chem. 2003 Nov 14;278(46):45382-90
pubmed: 12958312
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Adv Exp Med Biol. 2007;597:131-51
pubmed: 17633023
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
Scand J Immunol. 2007 May;65(5):479-86
pubmed: 17444959
J Biol Chem. 2013 Apr 12;288(15):10914-22
pubmed: 23463508
Adv Exp Med Biol. 2009;647:8-36
pubmed: 19760064
J Biol Chem. 1995 Jun 2;270(22):13303-7
pubmed: 7768931
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
J Immunol. 2010 Aug 1;185(3):1577-83
pubmed: 20585032
Sci Signal. 2017 Jan 17;10(462):
pubmed: 28096513
J Immunol. 2006 Jan 1;176(1):346-56
pubmed: 16365427
Cancer Immunol Res. 2014 Jan;2(1):19-26
pubmed: 24416732
Cancer Immunol Immunother. 2011 Jul;60(7):1009-17
pubmed: 21479995
J Immunol. 2011 Aug 15;187(4):1754-63
pubmed: 21742972
Mol Immunol. 2011 Jul;48(12-13):1586-8
pubmed: 21605907
Sci Signal. 2018 Jan 02;11(511):
pubmed: 29295955
J Biol Chem. 2011 Apr 1;286(13):11226-35
pubmed: 21285457
Science. 2011 Aug 19;333(6045):1030-4
pubmed: 21852502
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
J Immunol. 2005 Jan 1;174(1):542-50
pubmed: 15611281
J Immunol. 2000 May 15;164(10):5313-8
pubmed: 10799893
Proteins. 2004 May 1;55(2):351-67
pubmed: 15048827